Immunotherapy-related interstitial lung disease: a call to improve risk stratification and diagnostic consistency

Résumé fourni par la source

Extract Immune checkpoint inhibitors (ICIs) are immunomodulatory monoclonal antibodies that enhance T-cell-mediated cytotoxicity and have significantly transformed the treatment and outcomes of many cancers [1]. The primary targets of checkpoint inhibition are programmed cell death receptor 1 (PD-1), its ligand programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) [2].

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.